Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- APPF +12.5%, BAH +6.7%, GBCI +4.1%, OLN +4%, ALV +3.5%, FHI +3.4%, AXP +3.1%, BBDC +1.3%, PFS +1%
Other news:
- PRCH +14.7% (receives $25mln with signing of strategic agreement with Aon)
- FATE +3.3% (Steven Cohen discloses 5% passive stake)
- TVTX +3.2% (exclusive licensing agreement with Renalys Pharma)
- BTMD +3.1% (approved a $20 million share repurchase program of the Company's common stock)
- AYI +3% (increases dividend; also increases share buyback program by 3 mln shares)
- VNDA +2.9% (announces patent allowance for PONVORY (ponesimod) in the U.S.)
- FRHC +2.7% (completion of external review of allegations made in short-seller report; "there was no evidence identified of sanctions evasion or dealing with sanctioned oligarchs")
- NSTB +2% (determination to continue corporate existence; holders of public shares to be paid trust fund distribution and retain shares)
- AOSL +1.2% (DOJ investigation closes)
- WSR +1% (favorable court ruling)
Analyst comments:
- COIN +4.7% (upgraded to Outperform from Perform at Oppenheimer)
- HCAT +3.7% (upgraded to Buy from Neutral at Guggenheim)
- SNAP +2.8% (upgraded to Buy from Hold at Deutsche Bank)
- ASR +1.9% (upgraded to Buy from Sell at Goldman)
- BFH +1.8% (upgraded to Outperform from Perform at Oppenheimer)
- PAC +1.2% (upgraded to Buy from Neutral at Goldman)